ReviewFrontiers in cardiovascular medicine2025
Pain in the body, harm to the heart: advances in research on the impact of chronic pain on cardiovascular diseases.
Review in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- The Impact of Comorbidities on Health-Related Quality of Life Among Patients with Rheumatoid Arthritis.Healthcare (Basel, Switzerland) · 2026Article
- Review
- Inflammatory potential of the diet and self-rated quality of life in Italian adults.Frontiers in nutrition · 2026Article
- Global and regional burden, temporal trends, and projections of chronic pain from 1990 to 2032, and its association with cardiovascular diseases: analyses based on global burden of diseases study 2021.Frontiers in public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic pain (CP) is highly prevalent, and a substantial proportion of patients concurrently suffer from cardiovascular diseases (CVD), suggesting a complex interplay between these two conditions. CP increases the risk of CVD through multiple mechanisms, including sympathetic overactivation, neuroimmune inflammatory responses, endocrine and metabolic dysregulation, and bidirectional regulation along the heart-brain axis. Moreover, pharmacological treatments traditionally used for CP, such as non-steroidal anti-inflammatory drugs (NSAIDs), opioids and related agents, are associated with heightened cardiovascular risks. In contrast, non-pharmacological interventions like spinal cord stimulation and cognitive behavioral therapy have demonstrated dual potential in alleviating pain and improving cardiovascular outcomes. There is an urgent need to focus on the comorbid mechanisms linking CP and CVD, to develop precise and individualized intervention strategies, and to integrate pain management into cardiovascular prevention and treatment frameworks, thereby optimizing interdisciplinary approaches to comorbidity prevention and care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.